NCT00003575 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00003575/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
filgrastim [clinicaltrials_resource:41632cab616527ebd0147e9974a5401b]etoposide [clinicaltrials_resource:7cb6076e8355e089ce983cf1f80658d9]ifosfamide [clinicaltrials_resource:a371eedecd1223a82190c7976312ee4f]recombinant interleukin-12 [clinicaltrials_resource:bc199cab22b647fa72ae3aed0017d0fc]Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma [clinicaltrials:NCT00003575]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00003575 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00003575/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
Bio2RDF identifier
NCT00003575/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a4df479e15ec87e5cf6d58e58b6e85
description [clinicaltrials_vocabulary:description]
All patients receive ifosfamid ...... troviral therapy during study.
identifier
clinicaltrials_resource:NCT00003575/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
title
NCT00003575 arm group 08a4df479e15ec87e5cf6d58e58b6e85
@en
type
label
NCT00003575 arm group 08a4df47 ...... 4df479e15ec87e5cf6d58e58b6e85]
@en